Related Experiment Video
Updated: Jan 5, 2026
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
Potential for predicting toxicity and response of fluoropyrimidines in patients
James F Eliason1, Attila Megyeri
1Barbara Ann Karmanos Cancer Institute, Department of Internal Medicine, Wayne State University School of Medicine, Detroit, MI 48230, USA. eliasonj@karmanos.org
Abstract:
The efficacy of cancer therapy is compromised by the fact that there are currently no good ways to predict which patients will benefit from treatment. This long standing goal is closer to becoming a reality as more is learned about the molecules that affect the activities of various therapeutic agents. The fluoropyrimidine antimetabolites drugs have been in clinical use for over 4 decades and the cellular proteins important for their activities have been studied in detail. The most important are the major target enzyme, thymidylate synthase (TS) and the rate limiting enzyme in the degradation pathway, dihydropyrimidine dehydrogenase (DPD), equally important for the analogue capecitabine is thymidine phosphorylase (TP), which is rate limiting for activation of this prodrug. A number of assays are available for these enzymes, including enzyme activity measurements. quantitative PCR for RNA expression and immunological methods for protein expression. With each of these methods, more clinical studies are required to validate their clinical usefulness.
Insights
Predicting cancer therapy response remains a challenge. Research into key enzymes like thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), and thymidine phosphorylase (TP) offers hope for personalized fluoropyrimidine treatment strategies.
Area of Science:
- Oncology
- Pharmacogenomics
Background:
- Predicting patient response to cancer therapy is crucial for treatment efficacy.
- Fluoropyrimidine antimetabolites have been used for over 40 years.
- Key enzymes like thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), and thymidine phosphorylase (TP) influence drug activity and metabolism.
Purpose of the Study:
- To highlight the importance of molecular markers in predicting patient response to cancer therapy.
- To discuss the role of specific enzymes in fluoropyrimidine efficacy.
- To emphasize the need for further clinical validation of predictive assays.
Main Methods:
- Enzyme activity measurements.
- Quantitative PCR for RNA expression analysis.
- Immunological methods for protein expression assessment.
Main Results:
- Established assays exist for measuring TS, DPD, and TP.
- These assays provide insights into the molecular mechanisms of fluoropyrimidine action.
- Further clinical studies are necessary to confirm the utility of these assays.
Conclusions:
- Understanding enzyme levels and activity can aid in predicting patient response to fluoropyrimidine drugs.
- TS, DPD, and TP are critical targets for personalized cancer treatment strategies.
- Clinical validation is essential to integrate these predictive markers into routine practice.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:25Mutagenicity and Carcinogenicity